Completed × Myelodysplastic Syndromes × Busulfan × Clear all Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Phase 2 Completed
34 enrolled 18 charts
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Phase 2 Completed
80 enrolled 56 charts
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Phase 2 Completed
7 enrolled 12 charts
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Phase 2 Completed
21 enrolled 24 charts
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
Phase NA Completed
10 enrolled 11 charts
FluBuBe
Phase 2 Completed
50 enrolled
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Phase 1/2 Completed
63 enrolled 16 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
FluBuATG
Phase 1 Completed
20 enrolled
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Phase 2 Completed
422 enrolled 19 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase 1 Completed
70 enrolled
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 3 Completed
256 enrolled 13 charts
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Phase 1 Completed
32 enrolled 12 charts
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase 2/3 Completed
361 enrolled 16 charts
AML/MDS/JMML
Phase 1 Completed
18 enrolled
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
14 enrolled
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Phase 2 Completed
76 enrolled 16 charts
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Phase NA Completed
87 enrolled 10 charts
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Phase 2 Completed
72 enrolled 10 charts
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase 3 Completed
233 enrolled 7 charts
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
Phase 2 Completed
125 enrolled
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase 1/2 Completed
47 enrolled 8 charts
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Phase 3 Completed
570 enrolled 3 FDA
Cord Blood Expansion on Mesenchymal Stem Cells
Phase 1 Completed
98 enrolled
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
20 enrolled 11 charts
ALBUM
Phase 2 Completed
16 enrolled 7 charts
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Phase 2 Completed
142 enrolled 11 charts
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Phase 2 Completed
45 enrolled 12 charts
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Phase 2 Completed
200 enrolled
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Phase 2 Completed
8 enrolled 8 charts
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
7 enrolled
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Phase 2 Completed
35 enrolled 11 charts
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
LCCC0510
Phase 1/2 Completed
54 enrolled 17 charts
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase 2 Completed
34 enrolled 19 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase 2 Completed
71 enrolled 12 charts
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1 Completed
33 enrolled
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase 4 Completed
72 enrolled 10 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Phase 2 Completed
82 enrolled
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Phase 2 Completed
96 enrolled 5 charts
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
Phase 3 Completed
240 enrolled
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Phase 1/2 Completed
92 enrolled 5 charts